Drug Profile


Alternative Names: E 4960; E 4961; E-4018

Latest Information Update: 24 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Esteve
  • Class Non-opioid analgesics; Pyrazoles; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Substance P release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Overactive bladder; Pain; Stress incontinence; Urinary incontinence

Most Recent Events

  • 24 Feb 2010 Cizolirtine is still in active development for Overactive bladder and Urinary incontinence
  • 29 Mar 2006 Esteve has completed enrolment in a phase II trial for Stress urinary incontinence in Europe
  • 28 Feb 2005 Phase-II clinical trials in Stress urinary incontinence in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top